Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Releases Companion Dx Guidance Broad In Scope, Limited In Detail

Executive Summary

FDA released long-awaited draft guidance on the development of drugs with companion diagnostics July 12, but the 12-page document’s concise nature left some in the industry longing for more insight.

You may also be interested in...



Singapore’s Dx Assay Pushing Fee-for-service Model In Companion Diagnostics

Dx assays Pte. Ltd. says its fee-for-service business model makes it a unique provider of companion diagnostics in a market set to boom globally as U.S. FDA and other regulators push for drug firms to develop diagnostics alongside drugs.

Enrichment Guidance To Prod Sponsors Toward Prospective Patient Stratification

The sensitivity and specificity of the target identification could determine size of the off-target population, CDER senior statistical advisor Robert O’Neill says at DIA/FDA meeting on revitalizing R&D.

FDA On Personalized Medicine: Don’t Skimp On Diagnostic Quality Development

A Center for Devices and Radiological Health representative tells a conference on drug/diagnostic co-development that it doesn’t matter how well designed a study for a therapeutic agent is if the accompanying biomarker-targeted test is not reliable and uniformly implemented.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel